TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Hamstring Muscle Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lunge Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tinnitus Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral Behavioral Survey Questions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of OCD symptoms (Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in Heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FACT-Neurotoxicity subscale (NtxS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: C. difficile relative abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ASD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 99mTc-ADAPT6 uptake (counts)/SUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 99mTc-ADAPT6 tumor-to-background ratio (SPECT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 99mTc-DARPinG3 uptake (counts)/SUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 99mTc-DARPinG3 tumor-to-background ratio (SPECT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Skala (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Birth Experience Scale-CEQ
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hospice Enrollment Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Length of Hospice Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Adaptive Behavior
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: IL6 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Silicone particles quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-prosthetic capsule thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Silicone particle's size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratometry values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens power (D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of unanticipated adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of preoperative diagnosis of vascular involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Long haul COVID-19 related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overall health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PointCheck Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume of urine collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total gastric fluid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Satiety scale (0-10)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Levels of Il-17 and Il-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence to study path
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Compliance to interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pain quantification on 0-10 scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative bleeding frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: postoperative bleeding volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fear during intravenous cannula insertion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain during intravenous cannula insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placebo-controlled similarity score during induced ischaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient compliance with the program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of bonding failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participants with local injection site changes
Endpoint domain: Adverse events/effects
Primary endpoint: number of participants with systemic changes in physical exam
Endpoint domain: Adverse events/effects
Primary endpoint: number of participants with vital signs changes resulting in a serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: number of participants with ECG changes resulting in a serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: number of participants with laboratory changes resulting in a serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with patch test responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Specific Levels of Functioning (SLOF)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Boston Carpal Tunnel Syndrome Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average change in eczema area and severity index (EASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: sustainable improvement of nurses' competency
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Latency, amplitude and velocity of peripheral nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: disabling stroke rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: new permanent pacemaker implantation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: moderate or severe prosthetic valve regurgitation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in IGA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute change in gravimetrically measured sweat production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Hyperhidrosis Disease Severity Scale (HDSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to aspirin use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Development of new Sub-Clinical Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum venglustat plasma concentration observed (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Social Connectedness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Perceived Social Support
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measurement of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Evaluation of Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Clinic self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of post-traumatic stress disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Percentage Agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in nocturnal symptoms intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in paresthesia intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of gastric motility disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stroke velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total strokes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile of GTAEXS617 as monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Dose Limiting Toxicities (DLTs) of GTAEXS617 as monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 Dose (RP2D) of GTAEXS617 as monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Safety profile of GTAEXS617 in combination with selected Standard of Care (SoC) regimens
Endpoint domain: Adverse events/effects
Primary endpoint: Dose Limiting Toxicities (DLTs) of GTAEXS617 in combination with selected Standard of Care (SoC) regimens
Endpoint domain: Adverse events/effects
Primary endpoint: Time up and go test-speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time up and go test-cadence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time up and go test-step length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diurnal Level 2 Hypoglycemia Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of CBD
Endpoint domain: Adverse events/effects
Primary endpoint: AUCinf of Nirmatrelvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUClast of Nirmatrelvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of Nirmatrelvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUCinf of Ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUClast of Ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of Ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: live birth rate per transfer
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of MSM/TGW who correctly performed HCVST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ottawa Bowel Preparation Scale (OBPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ratio of palpebral involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in corneal nerve fibre density (CNFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: physical activity target-cancer outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary target-red meat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiorespiratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tobacco use quit likelihood
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Motor and sensory block success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of slippage/movement of the clip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of immune-related adverse events (IrAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants using the data collection app and providing at least 3 responses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability measured using the System Usability Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability measured via a semi-structured interview
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Adherent Scalp Flaking Scale (ASFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Feasibility of remote health monitoring
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of remote health monitoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with ASCVD events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First cycle Dose Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Generalized Anxiety Disorder - 7
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fMRI BOLD univariate analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fMRI BOLD multivariate analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gait angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Central line-associated bloodstream infection (CLABSI) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Annualized Rate of New Lobar Cerebral Microbleeds (CMBs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: QT Interval Corrected Using Fridericia's Formula (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: perioperative glycemic variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: perioperative clinical outcomes after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Successful Intubation With One Attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Intubation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PND knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Hba1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MOAAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in corneal ECD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal Cord Injury Quality of Life (SCI-QOL) Resilience-Short Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Spinal Cord Injury Quality of Life (SCI-QOL) Positive Affect and Wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Revised Dyadic Adjustment Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of reflux esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Barrett esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of MAKE-30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of gene alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Overall Improvement of Poikiloderma of Civatte (POC) at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Overall Improvement of Poikiloderma of Civatte (POC) at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to first rescue analgesia request postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sural Sensory Nerve Conduction Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GMTs of serum HI antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMTs of HI sIgA antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility of preschool wheeze assessment tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Content validity of the questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in emotions after intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes of score: Fugl-Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return of spermatogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of patients achieving steroid-free clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Third-day opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: External torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of reinterventions
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative anastomotic leaking and intraluminal/intraperitoneal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Gingival inflammation measured by Modified Gingival Index (MGI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival inflammation measured by Bleeding Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental hypersensitivity evaluated by Shiff sensitivity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Live Births Without Congenital Anomalies
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Live Births With Congenital Anomalies
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Ectopic Pregnancies
Endpoint domain: Mortality/survival
Primary endpoint: Conditioned pain modulation (CPM) profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporal summation profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum hand force output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum hand muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PHQ-9 results post treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: modified rankin scale (mRS) score ≤ 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful intubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of patients with impulse control disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year Disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Airway Occlusion Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: spiritual well-being-first
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: spiritual well-being-last
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Diabetic Retinopathy Severity Scale (DRSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Negative predictive values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: susceptibility to pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in brain activation during an inhibitory control task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Loss of Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort and Overall Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Presence of Skin Rash
Endpoint domain: Adverse events/effects
Primary endpoint: Spot urine albumin-creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Spot urine protein-creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants Without Treatment-Related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced Free C5-associated BTH
Endpoint domain: Adverse events/effects
Primary endpoint: Healthy Eating Index (HEI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes